Navigation Links
Gentium's Defibrotide Seen as Active in Multiple Myeloma

NEW YORK--(BUSINESS WIRE)--Jun 27, 2007 - Gentium S.p.A. (Nasdaq: GENT) announced the presentation of both clinical and preclinical data that support the safety, activity, synergy and potential mechanism of action of Defibrotide in combination with anticancer therapy in multiple myeloma. Investigators presented both an update from the Company's ongoing Phase I/II clinical trial for patients with refractory or relapsed multiple myeloma with Defibrotide in combination with chemotherapy, as well as a pre-clinical study demonstrating the downregulation of a key regulatory enzyme supporting a novel mechanism of action for Defibrotide in myeloma. Data from both studies was presented at the XI International Myeloma Workshop in Kos, Greece, 25-30 June, 2007.

In the first study, investigators led by Dr Antonio Palumbo of The Italian Multiple Myeloma Study Group, presented data from an ongoing multi-center, phase I/II clinical trial for relapsed or refractory multiple myeloma patients. This study is being conducted in an effort to define the maximum tolerated dose (MTD), safety and potential efficacy of the combination of melphalan, prednisone, thalidomide and Defibrotide (MPTD). Nineteen patients, who received at least three cycles of MPTD were evaluable for toxicity and response. Three escalating dose levels of Defibrotide were evaluated in combination with standard doses of melphalan, prednisone and thalidomide. No other thromboprophylaxis was administered. After a median of 3 cycles, the major response rate, including complete and partial remission was 53% (1CR, 1nCR and 7PR). Responses were seen in all three Defibrotide dose levels. Follow up remains limited and the durability of response appears favorable. MTD was not reached in any cohort. Hematological toxicities (greater than/equal to Grade 3) included neutropenia (47%), thrombocytopenia (10%), anemia (21%), non-hematological toxicities greater than/equal to grade 3 were observed in less than 5% of patients. Impor tantly only one DVT has been seen to date and no significant peripheral neuropathy has been reported.

In a preclinical study presented by Dr. Cinara Echart, Gentium's Manager of Molecular Biology, at the same meeting, Defibrotide demonstrated the ability to significantly downregulate heparanase gene expression and activity in myeloma cell lines in a dose dependent manner (p less than 0.01). In addition, Defibrotide decreases the myeloma cell invasion through the Matrigel matrix in vitro by 50%. Elevated heparanase expression in humans has been correlated with advanced progression and metastasis of many tumor types, including myeloma. Heparanase acts as a key mechanism for breakdown of extracellular matrix to facilitate tumor invasion and metastasis.

Dr. Antonio Palumbo commented, "The combination of MPTD is promising both in terms of activity and tolerability with the low rate of DVT being especially interesting. Moreover, the preclinical studies with Defibrotide are intriguing, suggesting a wider role for this drug as an orally biovavailable agent in combination with chemotherapy as a potential treatment for multiple myeloma."

About Gentium

Gentium, S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the research, development and manufacture of drugs to treat and prevent a variety of vascular diseases and conditions related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted a Fast Track Designation by the U.S. FDA to treat Severe VOD in recipients of stem cell transplants, Orphan Drug status by the U.S. FDA to treat and prevent VOD and Orphan Medicinal Product Designation by the European Commission to treat and prevent VOD.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20F filed with the Securities and Exchange Commission under the caption "Risk Factors."


Gary Gemignani, 212-332-1666
Chief Financial Officer


Related medicine technology :

1. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
2. Gentiums Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting
3. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
4. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
5. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
6. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
7. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
8. Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkins Lymphoma Appears Safe and Active in a Phase I/II Study
9. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
10. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
11. Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
Post Your Comments:
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
Breaking Medicine News(10 mins):